Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s):  FENC

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.


TSX:FRX - Post by User

Comment by commissionson Sep 27, 2004 11:52am
380 Views
Post# 7968973

RE: 1 Million

RE: 1 Million SS there will NOT be a roll back until we get to the Nasdaq!! As a matter of fact the reason the symbol choosen for the Amex was ADH and not AHX was that AHXX was not available on the Nasdaq but ADHX was. Couple of observations of the trading lately. The volume has been good for a few reasons: 1. it appears as though the Orion Conference went well ( the old Yorkton Sec)as they have been buying a fair bit , as has Griffiths Mcburney (GMP ).As has Dhlouy. 2. it also appears as though the seller has finished because if he was willing to sell his stock down to his ACB of .35 previously AND RIDE UP THE WARRANTS HE WOULD SURELY BEEN SELLING THE LAST COUPLE OF DAYS AS THERE WAS 500K ON THE BID DOWN TO .38 Interesting to note that a huge offer that had been at .52 for 100k - 1 order was yanked last thurs. 3. now that the US listing is now longer an 'if' but rather a 'when' I believe people will want to own this stock before our American freinds start to accumulate it. I will go out on a limb an predict the sort of trading that we will see: If there is still an overhang-and this may be 12-15 million shares or if may only be as little as a couple million the stock may trade huge volume and only get to .60- .80 range until its gone then gap up with no supply ( in the last 8 months or so we have traded 13 mill. shares approx and probably 8-10 million was institutional- the ones with the warrants. Or we could just see a steady move right up and through a $1 and if the US participation is strong then we could head for my previous thought of $3US + by years end if the news flow is strong and I believe that it will be!! Commissions
Bullboard Posts